Severe food allergy patients get continued access to dupilumab
NCT ID NCT06631677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program offers continued treatment with dupilumab to adults who have severe IgE-mediated food allergies and were previously treated with linvoseltamab and dupilumab in an earlier study. The goal is to provide ongoing access to the medication for those who completed the parent study. Only adults who finished the prior study without serious side effects are eligible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dupilumab
What this could lead to
If successful, this program could help maintain control of severe food allergies in adults who have already received initial treatment.
What could go wrong
This is an expanded access program, not a formal trial, so it provides limited data on long-term safety or effectiveness. It only includes a small, specific group of patients from a prior study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••